Circulating free DNA concentration as a marker of disease recurrence and metastatic potential in lung cancer.

Authors:
Soudeh Ghafouri-Fard
Soudeh Ghafouri-Fard
Shahid Beheshti University of Medical Sciences
Iran
Adnan Khosravi
Adnan Khosravi
Shahid Beheshti University of Medical Sciences
Iran
Elahe Motevaseli
Elahe Motevaseli
Tehran University of Medical Sciences
Iran
Sharareh Seifi
Sharareh Seifi
Shahid Ghazi Tabatabai Hospital
Iran
Babak Salimi
Babak Salimi
Children's Memorial Hospital
United States

Clin Transl Med 2019 Apr 18;8(1):14. Epub 2019 Apr 18.

Department of Medical Genetics, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran.

Background: Plasma circulating cell-free (cf) DNA is regarded as a source of tumor DNA. Based on availability of blood tissue for the purposes of early detection of cancer and patients' follow-up, several studies have evaluated concentration of cf DNA in cancer patients in association with tumor features. In the present study, we assessed concentration of cf DNA in lung cancer patients with two commercial kits (MN and QIAGEN) to find whether it can be used as a prognostic biomarker.

Results: Primary cf DNA concentrations as measured by QIAGEN kit was significantly higher in patients who died in the follow-up period compared with alive patients (P = 0.007). Moreover, the concentrations as measured by both methods were higher in patients who experienced recurrence in the follow-up period compared with patients without recurrence (P = 0.008 and 0.007 for MN and QIAGEN kits respectively). Significant associations were also found between cf DNA concentrations and tumor stage (P = 0.005 and 0.02 for MN and QIAGEN kits respectively). Notably, cf DNA concentration was higher in metastatic tumors compared with non-metastatic tumors in association with number of involved organs. Based on the AUC values, both kits could differentiate metastatic cancers from non-metastatic ones with accuracy of 98%.

Conclusions: The current study highlights the accuracy of cf DNA concentrations for prediction of disease course in lung cancer patients.

Download full-text PDF

Source
https://clintransmed.springeropen.com/articles/10.1186/s4016
Publisher Site
http://dx.doi.org/10.1186/s40169-019-0229-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6473013PMC
April 2019
3 Reads

Publication Analysis

Top Keywords

dna concentrations
12
lung cancer
12
cancer patients
12
dna
9
concentration dna
8
follow-up period
8
qiagen kits
8
period compared
8
higher patients
8
concentrations measured
8
dna concentration
8
patients
7
cancer
5
recurrence follow-up
4
compared patients
4
experienced recurrence
4
patients experienced
4
measured methods
4
methods higher
4
patients recurrence
4

References

(Supplied by CrossRef)
Article in Nat Rev Cancer
H Schwarzenbach et al.
Nat Rev Cancer 2011
Article in Eur Respir J
C Tissot et al.
Eur Respir J 2015
Article in J Thorac Oncol
S Cargnin et al.
J Thorac Oncol 2017
Article in Lung Cancer
R Zhang et al.
Lung Cancer 2010
Article in Oncotarget
B Ai et al.
Oncotarget 2016
Article in JAMA Oncol
N Karachaliou et al.
JAMA Oncol 2015
Article in Am J Clin Oncol
MM Oken et al.
Am J Clin Oncol 1982
Article in Chest
DE Ost et al.
Chest 2013
Article in Clin Cancer Res
JM Silva et al.
Clin Cancer Res 2002
Article in Sci Transl Med
C Bettegowda et al.
Sci Transl Med 2014
Article in Oncol Lett
JL Park et al.
Oncol Lett 2012

Similar Publications